Treatment for H. pylori infection using tegoprazan and amoxicillin
A Feasibility Study of Tegoprazan and Amoxicillin Dual Therapy for the Treatment of Helicobacter Pylori
This study is testing if a combination of tegoprazan and amoxicillin can effectively get rid of H. pylori infections in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Soonchunhyang University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT06950489 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of a dual therapy regimen combining tegoprazan, a potassium-competitive acid blocker, and amoxicillin for eradicating Helicobacter pylori infections. The approach aims to improve treatment outcomes by enhancing the stability and activity of amoxicillin in a higher gastric pH environment. The study will assess the success rate of H. pylori eradication and patient compliance with the treatment protocol over a specified duration. Participants will undergo gastroscopy and H. pylori testing as part of the evaluation process.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 20 to 80 who can undergo gastroscopy and H. pylori testing.
Not a fit: Patients with severe systemic diseases, advanced chronic liver disease, or a history of gastric surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a highly effective alternative for patients suffering from H. pylori infections, especially in cases where traditional therapies have failed.
How similar studies have performed: Previous studies have shown promising results with similar dual therapy approaches, indicating potential for success in this novel treatment regimen.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gastroscopy can be performed * H. pylori test and pathological analysis can be performed Exclusion Criteria: * Age \< 20 or \> 80 years * Anemia (serum hemoglobin level \< 10 g/dL) * Severe systemic disease * Advanced chronic liver disease * Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics * History of H. pylori eradication * Drug allergy to antibiotics * History of gastric surgery * Recent history of upper gastrointestinal bleeding
Where this trial is running
Seoul
- Digestive Disease Center, Soonchunhyang University Hospital — Seoul, Korea, Republic of (Recruiting)
Study contacts
- Study coordinator: Jun-Hyung Cho, M.D.
- Email: chojhmd@naver.com
- Phone: +82-2-709-9202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.